Cancer Research

NEWS: Encouraging data released for EZH2 inhibitor study for malignant mesothelioma

One of this year’s American Society for Clinical Oncology (ASCO) updates in mesothelioma included the release of the first results for the Phase 2 Study of the EZH2 inhibitor, tazemetostat, for malignant mesothelioma, presented by the chair of the board of the Mesothelioma Applied Research Foundation (Meso Foundation), Marjorie Zauderer, MD.
This study enrolled 61 BAP1 […]



Meso Foundation Reaches $10 Million in Research Grants Funded

With the conclusion of its latest funding cycle, the Mesothelioma Applied Research Foundation has reached the milestone of $10 million in grant funding awarded to the most promising mesothelioma research projects across the globe. The Foundation is the only non-governmental institution to fund mesothelioma research through a transparent, merit-based process modeled after the National Institutes […]


Mesothelioma Researcher Authors Journal Article on CAR T-cell Therapy

Mesothelioma researcher and Meso Foundation grant recipient Prasad S. Adusumilli, MD, FACS, FCCP, of the Memorial Sloan Kettering Cancer Center (MSKCC) was an author on the review article CAR T-cell therapy for lung cancer and malignant pleural mesothelioma recently published in Translational Research: The Journal of Laboratory and Clinical Medicine.
Dr. Adusumilli is a thoracic surgeon-scientist […]


Updates in Mesothelioma Research from ASCO 2017

The American Society of Clinical Oncology (ASCO) held its Annual Meeting on June 2-6, 2017 in Chicago. The Meso Foundation’s CEO, Melinda Kotzian, had the opportunity to attend the conference and hear the latest news reported in mesothelioma research.
Hedy Lee Kindler, MD, of the University of Chicago, presented a poster on the results from a […]